• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Phathom Pharmaceuticals, Inc. - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.2608 -0.0307 (-10.53%)
Official Closing Price Updated: 4:15 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about VivoSim Labs, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
VivoSim Labs, Inc. (NASDAQ: VIVS) Surges, Anthropic (NASDAQ: ANT) Opening Day and More Tech Inside
November 19, 2026
Via AB Newswire
Topics Artificial Intelligence Initial Public Offering
News headline image
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
November 19, 2026
Liver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind™ testing part of its regular flow of ongoing... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
November 16, 2026
New data on 10 compounds pulled due to unforeseen liver tox highlight how VivoSim’s models often easily catch clinical failure risk missed by animal models, using a complex approach that leverages... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Labs and Chemveda Move Human-Tissue Testing Earlier in AI Drug Development
November 13, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground
November 11, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
November 10, 2026
Company to feature two scientific poster presentations highlighting that its multiparametric approach delivers superior predictive power for both its DILI risk stratification and gastrointestinal... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Post-Midterm Market Sectors and Companies Inside to Watch
November 05, 2026
Via AB Newswire
News headline image
3 Stocks Under $1: INO, VIVS, FNUC in Focus for November
November 03, 2026
Via AB Newswire
News headline image
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
November 03, 2026
Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
October 21, 2026
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
5 Biotech Stocks’ TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer’s, Cardio and Cancer Research Milestones
October 13, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch
October 07, 2026
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
October 07, 2026
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via AB Newswire
News headline image
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
September 28, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026
Via AB Newswire
News headline image
Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
September 21, 2026
Via AB Newswire
Topics Government
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
September 21, 2026
Via AB Newswire
Topics Animal Testing
News headline image
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026
Via AB Newswire
Topics Artificial Intelligence Energy
News headline image
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
September 14, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
September 10, 2026
Via AB Newswire
News headline image
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
September 02, 2026
Via AB Newswire
News headline image
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
September 01, 2026
Via AB Newswire
Topics Artificial Intelligence Supply Chain
News headline image
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 01, 2026
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
September 01, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
August 26, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
August 26, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
August 25, 2026
Via AB Newswire
Topics Animal Testing Artificial Intelligence
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap